1R01CA248741-01A1 (PI: Carbone, Dikov) begins today.
NIH-NCI
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
Goal: To evaluate (1) the safety and tolerability of combination PBF-1129 with nivolumab, (2) the correlation between immunological parameters and adenosine generation, the microbiome and signaling, and (3) the efficacy of PBF-1129 in targeting adenosine-mediated immunosuppression.
Role: Co-Investigator